<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>BioAI 日知 · 虚拟药物研发</title><link>https://bioai-rizhi.pages.dev</link><description>来源原文索引；自动归类不等于事实复核。预印本保留状态。</description><language>zh-cn</language><ttl>60</ttl><atom:link href="https://bioai-rizhi.pages.dev/feed.xml?topic=drug-discovery" rel="self" type="application/rss+xml"/><item><guid isPermaLink="false">bioai:307f6140-95df-486d-abc3-bf9472df461a</guid><title>Isomorphic Labs enters into a strategic research collaboration with MSD</title><link>https://www.isomorphiclabs.com/articles/isomorphic-labs-enters-into-a-research-collaboration-with-msd</link><description>[Isomorphic Labs official announcements] Listen: Spotify Apple Podcasts Isomorphic Labs announces a strategic research collaboration with global pharmaceutical leader MSD. This collaboration brings together Isomorphic Labs’ AI approach to drug discovery with MSD’s rich proprietary data resources and deep discovery exper</description><pubDate>Thu, 19 Nov 2026 00:00:00 GMT</pubDate></item><item><guid isPermaLink="false">bioai:1e88c556-4b32-43a7-a2cb-c407398f46ef</guid><title>Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis</title><link>https://ir.recursion.com/news-releases/news-release-details/recursion-announces-alignment-fda-registrational-phase-3-trial</link><description>[Recursion official investor newsroom] Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis November 18, 2026 at 4:59 AM EST PDF Version REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease</description><pubDate>Wed, 18 Nov 2026 09:59:32 GMT</pubDate></item><item><guid isPermaLink="false">bioai:3ca326df-5073-411b-b3fb-56cfd950d522</guid><title>一年融三轮！晶泰孵化企业耀速科技再获数千万战略投资</title><link>https://www.xtalpi.com/%e4%b8%80%e5%b9%b4%e8%9e%8d%e4%b8%89%e8%bd%ae%ef%bc%81%e6%99%b6%e6%b3%b0%e5%ad%b5%e5%8c%96%e4%bc%81%e4%b8%9a%e8%80%80%e9%80%9f%e7%a7%91%e6%8a%80%e5%86%8d%e8%8e%b7%e6%95%b0%e5%8d%83%e4%b8%87%e6%88%98/</link><description>[XtalPi official Chinese RSS] 近日，晶泰科技（2228.HK）孵化的 3D 生物智能创新企业耀速科技（Xellar）宣布完成数千万元新一轮战略融资，本轮融资获得上海国投先导，石药国方基金等相关投资主体支持。 本轮融资将重点用于 “3D Bio Intelligence（3D 生物智能）” 平台的持续建设，深化器官芯片、人工智能与自动化实验技术的融合，加速高质量人源化生物数据积累、生物机制解析及 AI 模型能力建设，推动面向下一代药物研发的生物智能基础设施持续升级。 此次战略投资进一步体现了国资力量与产业资本对耀速科技技术创新能力及长期发展潜力的认可，也将助力耀速加速构建以真实生物实验</description><pubDate>Wed, 18 Nov 2026 07:18:00 GMT</pubDate></item><item><guid isPermaLink="false">bioai:aa89cfee-8005-4c07-ad6b-a0b92e26c5f6</guid><title>Systematic Characterization of Clinically Actionable Antibody-Drug Targets Across Solid Tumors to Advance Precision Oncology</title><link>https://doi.org/10.1158/2159-8290.cd-26-1021</link><description>[Crossref REST API] Abstract The rapid expansion of antibody therapeutics is shifting the clinical bottleneck from drug availability to precise patient selection. We systematically characterize 87 clinically actionable tumor-associated antigens across solid tumors by integrating transcriptomic, prot</description><pubDate>Wed, 18 Nov 2026 00:00:00 GMT</pubDate></item><item><guid isPermaLink="false">bioai:0d9cfcc3-ee4d-46de-ac7b-7b8fc9355f24</guid><title>Isomorphic Labs announces Series C investment round</title><link>https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-series-c-investment-round</link><description>[Isomorphic Labs official announcements] Listen: Spotify Apple Podcasts Isomorphic Labs announces it has raised $5 Billion in Series C funding. The round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz (a16z) and several other new investors, with continued significant investment from Alphabet.</description><pubDate>Tue, 17 Nov 2026 00:00:00 GMT</pubDate></item><item><guid isPermaLink="false">bioai:b76152cb-dead-457c-b78a-533783f050a6</guid><title>Building a new path to make medicines with AI</title><link>https://www.isomorphiclabs.com/articles/building-a-new-path-to-make-medicines-with-ai</link><description>[Isomorphic Labs official announcements] Listen: Spotify Apple Podcasts The Scale Solving all disease is one of the most monumentally complex challenges in science. Today, for the first time, AI provides the foundation to make it achievable. Tackling the frontier of human health is our mission, and it means identifying </description></item><item><guid isPermaLink="false">bioai:daa8f09a-595e-44cc-a62e-9cf14d84804a</guid><title>向深海要答案：晶泰科技携手伙伴，布局海洋生物智能研发</title><link>https://www.xtalpi.com/%e5%90%91%e6%b7%b1%e6%b5%b7%e8%a6%81%e7%ad%94%e6%a1%88%ef%bc%9a%e6%99%b6%e6%b3%b0%e7%a7%91%e6%8a%80%e6%90%ba%e6%89%8b%e4%bc%99%e4%bc%b4%ef%bc%8c%e5%b8%83%e5%b1%80%e6%b5%b7%e6%b4%8b%e7%94%9f%e7%89%a9/</link><description>[XtalPi official Chinese RSS] 近日，晶泰科技（ 2228.HK ）与自然资源部第三海洋研究所、鹭江创新实验室及厦门火炬集团分别签署战略合作协议。各方将围绕海洋生物资源挖掘、海洋药物发现、海洋生物材料及功能制品开发等方向展开合作，推动人工智能（AI）与机器人技术在海洋生物智造领域的应用。 聚焦海洋生物资源, 建设智能化研发平台 在科研合作方面，晶泰科技将与自然资源部第三海洋研究所围绕海洋生物资源库开展合作，重点挖掘活性菌株、基因组、极端酶及功能小分子化合物等资源，并共同建设海洋生物制造综合研发平台，开发海洋药物等高端产品。 与鹭江创新实验室的合作则将依托「Ocean BioX」（未来海</description><pubDate>Thu, 12 Nov 2026 02:47:09 GMT</pubDate></item><item><guid isPermaLink="false">bioai:bb8dc67a-61b3-4444-b411-11d8e7d4f116</guid><title>晶泰科技与高博医疗集团签署战略合作协议，共探AI赋能实验室智能化新路径</title><link>https://www.xtalpi.com/%e6%99%b6%e6%b3%b0%e7%a7%91%e6%8a%80%e4%b8%8e%e9%ab%98%e5%8d%9a%e5%8c%bb%e7%96%97%e9%9b%86%e5%9b%a2%e7%ad%be%e7%bd%b2%e6%88%98%e7%95%a5%e5%90%88%e4%bd%9c%e5%8d%8f%e8%ae%ae/</link><description>[XtalPi official Chinese RSS] 近日，晶泰科技（ 2228.HK ）与高博医疗集团签署战略合作协议，双方将以联合打造 AI 流式细胞自动化分析平台为切入点，结合晶泰科技在人工智能算法、实验室自动化等领域的技术积累，以及高博医疗集团在临床诊疗、研究与转化医学领域的专业积累和临床资源优势，探索人工智能与临床医学的深度融合，推动实验室向标准化、智能化方向发展。 聚焦临床诊断痛点, 探索AI赋能流式细胞分析 流式细胞术是血液系统疾病免疫分型、疾病评估及临床研究中的重要技术手段。 传统多色流式分析流程涉及荧光补偿校准、细胞分群、逐级人工设门等多个复杂环节，高度依赖医师临床经验，分析效率和结果一致</description><pubDate>Wed, 11 Nov 2026 09:30:37 GMT</pubDate></item><item><guid isPermaLink="false">bioai:bd302d9c-235c-43a1-83e3-de87eed374e2</guid><title>Anthropic bought a one-person, AI-powered biotech: is this drug discovery&#39;s future?</title><link>https://pubmed.ncbi.nlm.nih.gov/43015439/</link><description>[PubMed / NCBI E-utilities] Anthropic bought a one-person, AI-powered biotech: is this drug discovery&#39;s future?</description><pubDate>Wed, 11 Nov 2026 00:00:00 GMT</pubDate></item><item><guid isPermaLink="false">bioai:a83387c8-7774-4460-8b6d-e169555999be</guid><title>Are AI tech giants hijacking drug discovery?</title><link>https://doi.org/10.1038/s41587-026-03382-z</link><description>[Crossref REST API] Are AI tech giants hijacking drug discovery?</description><pubDate>Tue, 10 Nov 2026 00:00:00 GMT</pubDate></item><item><guid isPermaLink="false">bioai:d42d8cd9-953a-45de-870e-d6927be961dd</guid><title>皮尔法伯集团与晶泰科技宣布达成一项AI驱动药物发现的合作</title><link>https://www.xtalpi.com/%e7%9a%ae%e5%b0%94%e6%b3%95%e4%bc%af%e9%9b%86%e5%9b%a2%e4%b8%8e%e6%99%b6%e6%b3%b0%e7%a7%91%e6%8a%80%e5%ae%a3%e5%b8%83%e8%be%be%e6%88%90%e4%b8%80%e9%a1%b9ai%e9%a9%b1%e5%8a%a8%e8%8d%af%e7%89%a9%e5%8f%91/</link><description>[XtalPi official Chinese RSS] 法国卡斯特尔市/中国深圳 – 2026年11月6日，皮尔法伯集团与晶泰科技（2228.HK）宣布达成一项合作协议。双方将在肿瘤领域联合开展多个研发项目，共同发现新型临床候选药物，并有望拓展至皮肤病、罕见病等领域。 根据协议，晶泰科技将依托其一体化的“AI+机器人”核心能力，针对未披露的靶点从头设计并交付新型小分子治疗药物。皮尔法伯集团将发挥其在疾病生物学、药物发现、转化研究和临床开发领域的经验，筛选、推进最有前景的化合物，并负责后续的临床与商业开发。 此次合作体现了双方在探索具有挑战性、且长期以来被认为难以成药的靶点领域的共同意愿。这一领域不仅存在巨大的</description><pubDate>Mon, 09 Nov 2026 00:00:28 GMT</pubDate></item><item><guid isPermaLink="false">bioai:df9f964e-ac6d-4902-8e22-40c2c981accf</guid><title>Structure of chlorophyll synthase in complex with the LHC-like protein HliD.</title><link>https://pubmed.ncbi.nlm.nih.gov/43003881/</link><description>[PubMed / NCBI E-utilities] Chlorophyll synthase (ChlG) is a transmembrane enzyme that attaches the tetraprenyl tail to chlorophyllide to produce chlorophyll a, the key pigment of oxygenic photosynthesis. In the cyanobacterium Synechocystis sp. PCC 6803, ChlG forms a complex with the light-harvesting comple</description><pubDate>Mon, 09 Nov 2026 00:00:00 GMT</pubDate></item><item><guid isPermaLink="false">bioai:5fbdb4fa-f908-4dc8-a9b2-4f42021e92f3</guid><title>The Transformation of Oncology Drug Development in China: Toward a New Phase of Innovation.</title><link>https://pubmed.ncbi.nlm.nih.gov/42999985/</link><description>[PubMed / NCBI E-utilities] China&#39;s oncology drug development ecosystem has shifted from rapid pipeline expansion toward clinical value-driven innovation. We review regulatory reform and the 2015 to 2025 evolution of clinical development across small molecules, mAbs, multispecific antibodies, antibody-drug </description><pubDate>Sun, 08 Nov 2026 00:00:00 GMT</pubDate></item><item><guid isPermaLink="false">bioai:a51ecd75-732d-49e8-b643-b6a66bbac719</guid><title>从 AI 预测到 AI 原生，药物发现如何向前一步？</title><link>https://www.xtalpi.com/%e4%bb%8e-ai-%e9%a2%84%e6%b5%8b%e5%88%b0-ai-%e5%8e%9f%e7%94%9f%ef%bc%8c%e8%8d%af%e7%89%a9%e5%8f%91%e7%8e%b0%e5%a6%82%e4%bd%95%e5%90%91%e5%89%8d%e4%b8%80%e6%ad%a5%ef%bc%9f/</link><description>[XtalPi official Chinese RSS] 从新靶点探索、小分子设计到已有药物的新用途开发，AI 正在参与越来越多的研究项目。 在 SWITCH 2026 期间晶泰科技举办的 “AI for Science: From Prediction to Discovery” 主题研讨会上，晶泰科技联合创始人兼首席创新官赖力鹏博士指出，随着项目向后续阶段推进，“ 最重要的是，你能以多快的速度验证 AI 生成的想法和设计。 ” “AI 药物发现正在从‘ AI 预测’走向‘ AI 原生’”。赖力鹏博士认为。所谓 AI 预测是指 AI 给出答案，人去验证；而 AI 原生，是指整个研发体系围绕 AI 重建，让验证</description><pubDate>Wed, 04 Nov 2026 09:03:00 GMT</pubDate></item><item><guid isPermaLink="false">bioai:d6747be3-83dd-4aa3-b07d-d889c534c833</guid><title>Comprehensive mapping of essential-gene interactions in M. tuberculosis</title><link>https://doi.org/10.1038/s41586-026-11212-0</link><description>[Crossref REST API] Abstract Mycobacterium tuberculosis , the causative agent of tuberculosis, remains the world’s deadliest pathogen 1 . Despite intensive study, many of its genes remain uncharacterized, which limits the insight that can be gained into tuberculosis biology and constrains drug devel</description><pubDate>Wed, 04 Nov 2026 00:00:00 GMT</pubDate></item><item><guid isPermaLink="false">bioai:f15c7f9e-0717-412f-a4b8-9e636c6adb8a</guid><title>AI + 机器人走向中东，探索生命科学新可能</title><link>https://www.xtalpi.com/ai%e6%9c%ba%e5%99%a8%e4%ba%ba%e8%b5%b0%e5%90%91%e4%b8%ad%e4%b8%9c%ef%bc%8c%e6%8e%a2%e7%b4%a2%e7%94%9f%e5%91%bd%e7%a7%91%e5%ad%a6%e6%96%b0%e5%8f%af%e8%83%bd/</link><description>[XtalPi official Chinese RSS] 近日，晶泰科技（XtalPi）与迪拜医科大学（Dubai Medical University，DMU）签署战略合作协议，双方将结合 DMU 的学术研究优势与晶泰科技的产业研发能力，探索人工智能（AI）与机器人技术在医学研究领域的创新应用，共同拓展阿联酋生命科学与医药创新的研究边界。 阿联酋正积极推动生命科学与制药创新产业发展，希望进一步提升其在全球生命科学领域的影响力。 通过此次合作，晶泰科技将与迪拜医科大学连接各自的科研资源与技术优势，为研究人员提供先进的科研基础设施、技术支持和国际交流机会，让更多科学想法有机会转化为具体的研究项目，也为科研人员和学</description><pubDate>Tue, 03 Nov 2026 07:58:36 GMT</pubDate></item><item><guid isPermaLink="false">bioai:c2a6849d-5d02-4473-a85c-61c3c7b1bdbb</guid><title>New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps</title><link>https://ir.recursion.com/news-releases/news-release-details/new-phase-2-rec-4881-data-presented-cga-igc-show-deep-durable</link><description>[Recursion official investor newsroom] New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps November 2, 2026 at 4:25 PM EST PDF Version Updated TUPELO results featured in a Presidential Plenary at CGA-IGC :</description><pubDate>Mon, 02 Nov 2026 21:35:09 GMT</pubDate></item><item><guid isPermaLink="false">bioai:c5db2656-0bc2-4901-b707-c4a476df6ca4</guid><title>Recursion Appoints Fred Hassan as Chair of the Board</title><link>https://ir.recursion.com/news-releases/news-release-details/recursion-appoints-fred-hassan-chair-board</link><description>[Recursion official investor newsroom] Recursion Appoints Fred Hassan as Chair of the Board November 2, 2026 at 4:05 PM EST PDF Version Salt Lake City, UT , Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced</description><pubDate>Mon, 02 Nov 2026 21:05:43 GMT</pubDate></item><item><guid isPermaLink="false">bioai:4ca1f3d7-7335-4443-88e1-da9786d81a9c</guid><title>SIGX1094 联合疗法 Ⅱ/Ⅲ 期临床获批启动</title><link>https://www.xtalpi.com/sigx1094-%e8%81%94%e5%90%88%e7%96%97%e6%b3%95-%e2%85%b1-%e2%85%b2-%e6%9c%9f%e4%b8%b4%e5%ba%8a%e8%8e%b7%e6%89%b9%e5%90%af%e5%8a%a8/</link><description>[XtalPi official Chinese RSS] 近日，晶泰科技（ 2228.HK ）孵化企业希格生科宣布，其自研 FAK/SRC 双靶点抑制剂 SIGX1094 联合信达生物 KRAS-G12C 抑制剂氟泽雷塞片（达伯特 ®） ，用于KRAS-G12C 突变阳性非小细胞肺癌的 Ⅱ/Ⅲ 期临床试验 ，正式获国家药监局 NMPA 批准。 这是 SIGX1094 继弥漫性胃癌之后，拿下的第二个核心适应症，也是晶泰科技 AI+类器官研发范式在实体瘤领域的又一次临床落地。 这一进展有望打破 KRAS-G12C 靶向治疗的耐药天花板，帮肺癌患者获得更长、更稳定的生存时间，也再次印证了晶泰科技平台持续产出高价值管线</description><pubDate>Mon, 02 Nov 2026 08:30:00 GMT</pubDate></item><item><guid isPermaLink="false">bioai:0802ce89-f2dc-4ee2-ac1c-397db41a5195</guid><title>晶泰自研创新药获FDA临床试验许可</title><link>https://www.xtalpi.com/%e6%99%b6%e6%b3%b0%e8%87%aa%e7%a0%94%e5%88%9b%e6%96%b0%e8%8d%af%e8%8e%b7fda%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e8%ae%b8%e5%8f%af/</link><description>[XtalPi official Chinese RSS] 10 月 28 日晶泰科技（ 2228.HK ）宣布，其自主研发的肠道限制性高选择性 pan-TRK 抑制剂 KQTD-126 已获得美国食品药品监督管理局（FDA）的新药临床试验（IND）许可，并计划于近期开展临床试验。 KQTD-126 主要面向肠易激综合征（IBS）及炎症性肠病（IBD）相关慢性肠道疼痛，通过兼具高活性、高选择性与肠道限制性的创新设计，有望在有效缓解肠道疼痛的同时，降低全身暴露及潜在不良反应风险，为慢性肠道疼痛患者提供新的治疗选择。 在 KQTD-126 的研发过程中，晶泰科技充分发挥 AI 算法与机器人自主实验平台的协同优势。 面</description><pubDate>Wed, 28 Oct 2026 02:37:33 GMT</pubDate></item><item><guid isPermaLink="false">bioai:db124845-c3fa-4f3a-b8d9-426bd099ec31</guid><title>挑战“不可成药”三十余年，这位哈佛科学家为何将目光投向中国？</title><link>https://www.xtalpi.com/%e6%8c%91%e6%88%98%e4%b8%8d%e5%8f%af%e6%88%90%e8%8d%af%e4%b8%89%e5%8d%81%e4%bd%99%e5%b9%b4%ef%bc%8c%e8%bf%99%e4%bd%8d%e5%93%88%e4%bd%9b%e7%a7%91%e5%ad%a6%e5%ae%b6%e4%b8%ba%e4%bd%95/</link><description>[XtalPi official Chinese RSS] 在制药行业，有些靶点被公认为 “不可成药”：科学家清楚它们与疾病的关联，却始终找不到能够有效干预的药物。但有一个人，花了三十多年，一直在和这件事较劲。 他叫 Gregory Verdine——哈佛大学化学荣休教授、DoveTree Medicines 创始人，也是化学生物学领域的重要学者。订书肽、分子胶、RAS，这些制药行业公认最难的赛道上，都留下了他的名字。 他先后创立或联合创立十余家生物技术企业，并亲眼见证自己早年参与推动的一条技术路线，转化为 2026 年获批上市的胰腺癌新药。 如今，67 岁的他把目光投向了中国。2025 年，他创立的 DoveT</description><pubDate>Tue, 27 Oct 2026 02:32:30 GMT</pubDate></item><item><guid isPermaLink="false">bioai:0bcc3931-d41a-4a44-a3f7-9b5acbf584f9</guid><title>Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3</title><link>https://ir.recursion.com/news-releases/news-release-details/recursion-host-webinar-focused-updated-rec-4881-fap-data-cga-igc</link><description>[Recursion official investor newsroom] Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3 October 26, 2026 at 4:05 PM EDT PDF Version Webinar will include earnings updates and REC-4881 data as well as KOL and patient panels, presented live from CGA-IGC on Tuesday, Nove</description><pubDate>Mon, 26 Oct 2026 20:05:29 GMT</pubDate></item><item><guid isPermaLink="false">bioai:bb4e1b9e-68ab-44f4-902f-b2e52a5fa41d</guid><title>Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers</title><link>https://www.iambic.ai/post/iambic-presents-updated-iam1363-clinical-data-at-esmo-2026</link><description>[Iambic official newsroom] IAM1363, now in a Phase 1/1b stud y , was designed using Iambic’s molecular superintelligence platform and brought to clinic al development in approximately two years D ata presented at ESMO 2026 demonstrates IAM1363 was well tolerated with low rates of Grade 3 or higher treatmen</description><pubDate>Mon, 26 Oct 2026 00:00:00 GMT</pubDate></item></channel></rss>